Udvalget for Humanmedicinske Lægemidler (CHMP) konstaterede, at der på grund af det lille antal patienter med disse sygdomme kun foreligger begrænsede oplysninger, der støtter godkendelse af Atriance, men fandt, at lægemidlet kan give nogle patienter mulighed for at gå videre til knoglemarvs - transplantation, så deres overlevelsesmulighed øges.
The Committee for Medicinal Products for Human Use (CHMP) noted that, due to the small number of patients with these diseases, the information to support the approval of Atriance is limited, but it agreed that the medicine could allow some patients to go on to receive a bone marrow transplant, increasing their chances of survival.